Stock Events

Stock Events

Palisade Bio 

$2.15
69
+$0.00+0% 08:25 Today

Statistics

Day High
2.17
Day Low
2.16
52W High
2.86
52W Low
0.53
Volume
31,595
Avg. Volume
-
Mkt Cap
374.68M
P/E Ratio
16.33
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.99
-1.34
-0.69
-0.04
Expected EPS
-0.061111
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-16.78MNet Income

Analyst Ratings

6.75Average Price Target
The highest estimate is 8.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PALI. It's not an investment recommendation.
Tesla
9
TSLA
Microsoft
8
MSFT
NVIDIA
8
NVDA
Coca-Cola
8
KO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, potentially overlapping with Palisade Bio's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences competes in the biopharmaceutical space, focusing on life-threatening diseases, similar to Palisade Bio's focus areas.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech company that develops innovative therapeutics, competing with Palisade Bio in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of pharmaceutical products, directly competing with Palisade Bio's business model.
Biogen
BIIB
Mkt Cap31B
Biogen competes with Palisade Bio in the biotechnology and pharmaceuticals sector, focusing on serious diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie operates in the same biopharmaceutical field as Palisade Bio, developing therapies for complex and serious diseases.
Merck
MRK
Mkt Cap335.14B
Merck & Co. is a global healthcare company that produces pharmaceuticals competitive with Palisade Bio's product pipeline.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a direct competitor in the pharmaceuticals sector, with a broad range of products that could compete with Palisade Bio's developments.
Novartis
NVS
Mkt Cap286.78B
Novartis is a global healthcare company with a diverse portfolio, including innovative medicines that could compete with Palisade Bio.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, competing with Palisade Bio in several therapeutic areas.

About

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Show more...
CEO
J. D. Finley
Employees
14
Country
United States
ISIN
US6963894026
WKN
000A4098S

Listings

STU
DE
7NS0.STU
MU
DE
7NS0.MU
F
DE
7NS0.F
XNAS
US
PALI

0 Comments

Share your thoughts

FAQ

What is Palisade Bio stock price today?▼
The current price of PALI is $2.15 USD — it has increased by +0% in the past 24 hours. Watch Palisade Bio stock price performance more closely on the chart.
What is Palisade Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Palisade Bio stocks are traded under the ticker PALI.
Is Palisade Bio stock price growing?▼
PALI stock has risen by +0.47% compared to the previous week, the month change is a +9.14% rise, over the last year Palisade Bio has showed a +168.41% increase.
What is Palisade Bio market cap?▼
Today Palisade Bio has the market capitalization of 374.68M
When is the next Palisade Bio earnings date?▼
Palisade Bio is going to release the next earnings report on November 16, 2026.
What were Palisade Bio earnings last quarter?▼
PALI earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.05 USD resulting in a +4.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Palisade Bio revenue for the last year?▼
Palisade Bio revenue for the last year amounts to 0 USD.
What is Palisade Bio net income for the last year?▼
PALI net income for the last year is -16.78M USD.
How many employees does Palisade Bio have?▼
As of August 18, 2026, the company has 14 employees.
In which sector is Palisade Bio located?▼
Palisade Bio operates in the Health & Wellness sector.
When did Palisade Bio complete a stock split?▼
The last stock split for Palisade Bio was on April 08, 2024 with a ratio of 1:15.
Where is Palisade Bio headquartered?▼
Palisade Bio is headquartered in CARLSBAD, United States.